PMID- 20532510
OWN - NLM
STAT- MEDLINE
DCOM- 20110523
LR  - 20131121
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 67
IP  - 4
DP  - 2011 Apr
TI  - Renal safety and efficacy of cisplatin-based chemotherapy in patients with a 
      solitary kidney after nephroureterectomy for urothelial carcinoma of the upper 
      urinary tract.
PG  - 769-74
LID - 10.1007/s00280-010-1349-2 [doi]
AB  - PURPOSE: Little information is available about changes in renal function after 
      cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The 
      authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy 
      for upper urinary tract-urothelial carcinoma (UUT-UC). METHODS: The data of 
      patients who underwent nephroureterectomy for UUT-UC and received CBCT for 
      adjuvant and/or palliative treatment were reviewed. Renal function changes and 
      renal function-related adverse events (AEs) were analyzed, and objective tumor 
      responses were assessed. RESULTS: Sixty patients were enrolled, and a median of 6 
      cycles (1-22) of CBCT were administered. After the 3rd cycle of CBCT, serum 
      creatinine levels were significantly higher than at baseline, whereas mean 
      creatinine clearances and estimated glomerular filtration rates were 
      significantly lower. These renal function indicators also tended to be lower than 
      baseline after the 6th-21st cycles, but these decreases were not significant. 
      Significant AEs (>/=grade 2) occurred in 10 patients (16.7%), and serious AEs 
      (>/=grade 3) developed in two that required temporary hemodialysis. Univariate 
      analysis revealed that a low estimated glomerular filtration rate at baseline was 
      related to the occurrence of a significant renal AE with borderline significance 
      (Hazard ratio = 3.284, P = 0.100). The overall tumor response rate was 30.2%, and 
      tumor response rates of 1st, 2nd, and 3rd line therapies were 36.4, 25.0, and 
      12.5%, respectively. CONCLUSIONS: Cisplatin-based chemotherapy can be 
      administered in the majority of patients with UUT-UC with a solitary kidney after 
      nephroureterectomy without inducing a serious AE, and provides acceptable 
      efficacy.
FAU - Cho, Kang Su
AU  - Cho KS
AD  - Urologic Oncology Clinic, Center for Prostate Cancer, National Cancer Center, 111 
      Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.
FAU - Joung, Jae Young
AU  - Joung JY
FAU - Seo, Ho Kyung
AU  - Seo HK
FAU - Cho, In-Chang
AU  - Cho IC
FAU - Chung, Han Soo
AU  - Chung HS
FAU - Chung, Jinsoo
AU  - Chung J
FAU - Lee, Kang Hyun
AU  - Lee KH
LA  - eng
PT  - Journal Article
DEP - 20100608
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antineoplastic Agents)
RN  - AYI8EX34EU (Creatinine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Transitional Cell/*drug therapy/pathology/surgery
MH  - Chemotherapy, Adjuvant/methods
MH  - Cisplatin/adverse effects/*therapeutic use
MH  - Creatinine/blood
MH  - Databases, Factual
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Kidney/*metabolism/pathology
MH  - Kidney Function Tests
MH  - Kidney Neoplasms/drug therapy/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy/methods
MH  - Palliative Care/methods
MH  - Treatment Outcome
MH  - Ureteral Neoplasms/drug therapy/pathology/surgery
MH  - Urologic Neoplasms/*drug therapy/pathology/surgery
EDAT- 2010/06/10 06:00
MHDA- 2011/05/24 06:00
CRDT- 2010/06/10 06:00
PHST- 2010/01/21 00:00 [received]
PHST- 2010/04/13 00:00 [accepted]
PHST- 2010/06/10 06:00 [entrez]
PHST- 2010/06/10 06:00 [pubmed]
PHST- 2011/05/24 06:00 [medline]
AID - 10.1007/s00280-010-1349-2 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2011 Apr;67(4):769-74. doi: 
      10.1007/s00280-010-1349-2. Epub 2010 Jun 8.